PRMC BRAIN Module Instructions for Initial Protocol Submission

The PRMC module in BRAIN lets you copy the current summary, protocol, consent, and attachments from ESP1 (the IRB module) into your submission to the DLDCCC PRMC.

The Administrative Contact in the protocol's ESP1 summary can create the PRMC submission in this module. As with ESP1, only the PI can submit the protocol the PRMC.

Protocols should be submitted to PRMC <u>after</u> review by the Program or Disease Working Group.

Important Notes

The IRB/ESP1 summary and protocol <u>cannot</u> be edited from the PRMC module. The PRMC module only has a copy ("read-only") from the IRB module.

Prepare your IRB/ESP1 submission first, as these materials are used by the PRMC for review. It is recommended that you submit to the PRMC while the IRB/ESP1 submission is still in <u>DRAFT</u> mode (not yet submitted to IRB); then, any changes required by the PRMC can be incorporated into the final version that is submitted to the IRB.

If you have already submitted to the IRB and then you make any changes to the summary, protocol, consent, or other documents during PRMC review, you MUST submit the changes to the IRB for approval, via ESP1, as an amendment.

Accessing PRMC module in BRAIN



Biomedical Research and Assurance Information Network
Electronic Submission of Proposals and Protocols
BRAIN

Home

Logout

ESP1 Electronic Submission of Protocols to Animal (IACUC) and Human (IRB) Committees

Animal protocol submissions and IACUC determinations.

Human protocol submissions and IRB determination tracking includes submissions for: determinations of engagement in human subjects research, determinations of non-human subjects research, exemptions, and requesting reliance on an external IRB.

ESP2 Electronic Submission of Proposals (grants, contracts, etc)

Grants, Subawards, Progress Reports, No Cost Extensions, Contracts, Clinical Trials, and other Sponsored Research Agreements are submitted and their status tracked here.

ECAT Electronic Certification and Training

Includes training modules or links to training systems required for human subject and animal model research.

EIFA Electronic Intramural Funding and Awards

Electronic application system for the Junior Faculty Seed Awards and the Basic & Clinical Collaborative Research Program

PRMC Protocol Review and Monitoring Committee

Electronic submission system for the Dan L. Duncan Cancer Center Protocol Review and Monitoring Committee.

EDFR Electronic Disclosure of Financial Relationships

Electronic disclosure of all financial interests that you have that may be related to your BCM institutional responsibilities. Entry into this section is the first step in complying with Research Conflict of Interest Policy requirements.

ERCOI Electronic Research Conflict of Interest

In this module you will be able to submit your electronic Significant Financial Interest (SFI) disclosure form related to a specific proposal for grant or contract funding.

ECOI Electronic Conflict of Interest

Module in support of the General Conflict of Interest Committee. Any existing or proposed relationship, transaction or other event which raises or may raise a potential conflict of interest can be disclosed in this module.

Gonoral Noticos



Creating the PRMC submission coversheet

> EC CHAIR > WG CHAIR > REVIEWER > WG MEMBER Welcome STACEY L BERG	
WG CORD	
<pre>> ADMINISTRATOR > INVESTIGATOR > View Click > Search "create" > Create</pre>	
Forme Logout	

Complete the "Initial Review Coversheet". (Top half shown here.)

	ew Coversheet
PRMC Protocol: 81	
PRMC Status: Draft	
Go To Section PRMC	C - Initial Coversneet ÷
**	⊟ ×
Seneral Protocol Information	
Select the appropriate working group:	
Adult CAGT Pediatric	
Expected Activation Date:	
expected Local Accrual - Annual:	
Expected Local Accrual - Total:	
Expected Duration of Accrual (months):	
Institutional Status/Study Priority	
Yes No	
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.):	Cow Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial intiated by and investigator from another institution):	Cow Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial initiated by and investigator from another institution):	Cow Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial initiated by and investigator from another institution): Research Category	Cow Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial initiated by and investigator from another institution): Research Category Verse Select the category which most accurately descre	Low Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional implementation: or participation in a multi-site trial initiated by and investigator from another institution): Research Category Please select the category which most accurately descr	Low Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial initiated by and investigator from another institution): Research Category Therapeutic: Clinical trial with therapeutic intent using of	Low Middle High
 Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial initiated by and investigator from another institution): Research Category Please select the category which most accurately description of cancer ristirug, nutritional, dietary, behavioral, or other intervention. 	Low Middle High
Yes No Please select the study's priority: Sponsor and/or Funding Source Check all that apply, and name the sponsor(s). National Cooperative Group: Other Externally Peer Reviewed (NIH, ACS, etc): Industry (design and implementation controlled by Pharma co.): Institutional (in-house, internally reviewed, including those conducted with industry sponsorship in which the institutional investigator is a primary contributer to design and implementation: or participation in a multi-site trial initiated by and investigator from another institution): Research Category Please select the category which most accurately descr Therapeutic: Clinical trial with therapeutic intent using of Supportive Care: Clinical trial intended to improve the dietary, behavioral, or other intervention.	Low Middle High

Complete the the "Initial Review Coversheet". (Bottom half shown here.) Click the Save icon when finished.

Supportive Care: Clinical trial intended to improve the comfort and quality of life for the patient using drugs, nutritional, dietary, behavioral, or other interventions.

Screening, Early Detection or Diagnostic: Clinical trial directly testing the efficacy of device, technique or procedure; or trial which tests for earlier or more accurate detection or diagnosis of disease.

Epidemiologic, Observational, or Outcome: Study among cancer patients and healthy populations that involve no intervention or alteration in the status of participants, e.g., surveillance, risk assessment, outcome, environmental, and behavioral studies.

Ancillary: Auxiliary study that is stimulated by, but not a required part of, a main clinical trial. Must be linked to an active trial, and only include patients accrued to that trial.

Correlative: Lab based study using specimens to assess cancer risk, outcomes, response to therapies, etc.

Expediated Review Determination

Does this protocol meet one or more of the following criteria? (select all that apply):

approved by the NCI Cancer Therapy Evaluation Program (CTEP), NCI Cancer Prevention and Control Protocol Review Committee, or the BMT Clinical Trials Network (CTN)

supported by an NIH funding mechanism (e.g., R01, U01, U10 etc) which required full peer review as part of the funding

Is a non-interventiion study and is not requesting DLDCC support

General Clinical Research Center Are you applying for GCRC review of this submission? Yes No

You must link your IRB protocol (from ESP1) to this PRMC submission. **NOTE**: Make sure the IRB/ESP1 summary and protocol are current and complete before attaching it to the PRMC submission. The PRMC module is making a <u>copy</u> of what is in ESP1, including the protocol summary, the consent form (Section Q), and all attachments (Section S).

The ESP1 IRB protocol does not need to be submitted to the IRB before it is attached here, but the DRAFT version must be completed.

Use the "plus sign" under Attach Protocols to find and select the H-number.

Initial Review Coversheet			
PRMC Protocol: 81 PRMC Status: Draft			
r Amo Otatus. Drait	Go To Section PRMC - Attach ESP1 Protocol ÷		
	+ + ×		
It is highly recommended t this coversheet. Before you you can only attach one pr update the protocol to PRM	It is highly recommended that you completed your protocol review for completeness in ESP1 before attach/submit this coversheet. Before you submit this coversheet, you can update the protocol as many time as you want. Since you can only attach one protocol to this coversheet, Please delete the previously attached irb protocol before you update the protocol to PRMC.		
Attached Protocols			
-			
T			
T			

Enter the IRB/ESP1 H-number, and click Go.

Protocols (ESP1)			
Protocol Type: Hu ESP1 Protocol Number: List Protocols	uman (Number Only, Do Not include H-)		

Protocols (ESP1)				
Protocol Type: ESP1 Protocol Number: List Protocols	Human 13501	(Number Only, Do Not include H-)		
	G0 F			

Or, you can click "List Protocols" and select from list, then click "Go".



Click the radio button to select protocol. Click Save.

Protocol Type: Human ESP1 Protocol Number: 13501 (Number Only, Do Not include H-) List Protocols					
		G	io		
Select		PROTOCOL NUMBER	STATUS	VERSION	ESP1 Protocol
Select	<u>UNIQUE_ID</u> 232399	PROTOCOL_NUMBER	STATUS Assigned to Committee	VERSION Renewal	ESP1 Protocol View Protocol

IRB/ESP1 protocol is now attached to the PRMC submission.

You may see this warning about "Review for Completeness":

Upload ESP1 Protocol to PRMC

Your protocol has not passed the ESP1 "Review for Completeness". It is highly recommended that you have an accurate protocol before attaching in the PRMC module. If you still want to attach this protocol please click the Save button below. Please be aware that attaching the ESP1 protocol might take several minutes.

You can override this warning, but it means that pieces are missing from your IRB summary in ESP1.

If you make any changes in ESP1, you need to repeat these steps to reattach the ESP1 protocol to your PRMC submission to include those changes. Click "View Protocol Summary" to check that the correct protocol is attached.



Click right arrow to continue



Additional Attachments for the PRMC

Initial Review Coversheet		
PRMC Protocol: 81 PRMC Status: Draft Go To Section PRMC - Attach Document \$		
$\leftrightarrow \rightarrow \times$		
Hints To revise an attachment, you must delete the old attachment and upload the new attachment.	_	
Attached files may be downloaded from the server by clicking on the file name and selecting "Save file to disk". It n be modified and re-uploaded. Please review your attachments and make sure all of them can be opened before submitting your protocol. File na	The DW must be	G/Program Score Sheet attached here.
special characters such as % or # will make the file inaccessible. MAC users please make sure there are no spaces included in your attachment file name.	You have	e the option to attach
Principal investigators: Please remember that Revierers and Board Members must have the same or a similar app your attachment was created in to open it.	any othe Remember ESP1 Sect copied ov	er documents as well. er: any documents from ion S have already been ver, and do not need to be
Select File to Upload: Browse	repeated	here.
Attachment Description:	~	Name the attachment something descriptive



Click "Submit" to send the protocol to the PRMC. Submission must be done by the PI. You will receive an email confirming your submission.

Initial Review Coversheet PRMC Protocol: 33 PRMC Status: Draft Go To Section PRMC - Verify/Submit ۵. PRMC Verify/Submit It is highly recommended that you complete the protocol summary in ESP1, including the "Review for Completeness" step, before you attach the protocol below. Before you submit this study to the PRMC, you can update the ESP1 protocol summary as many times as you want. Only one protocol can be attached at a time. If you update the ESP1 summary after it has been attached below, please delete it, and re-attach it so the PRMC submission is also updated. Review

Questions?

Contact prmc-dldcc@bcm.edu